WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward Incorporated (NASDAQ: PFWD), a provider of data management solutions for clinical trials and drug safety, announced today that it has filed a preliminary prospectus supplement with the U.S. Securities and Exchange Commission relating to an underwritten public offering of 5,500,000 shares of its common stock under an effective shelf registration statement. The underwriters will have an option to purchase up to an additional 825,000 shares from Phase Forward to cover over-allotments, if any.
